BTIG Upgrades NeoGenomics to Buy, Announces $28 Price Target

Benzinga Newsdesk www.benzinga.com Positive 68.7%

Neg 0% Neu 0% Pos 68.7%

BTIG analyst Mark Massaro upgrades NeoGenomics (NASDAQ:NEO) from Neutral to Buy and announces $28 price target.

Comments

No comments yet. Be the first!